Yes, we need improved biomarkers of aging. Once we have biomarkers that are accurate enough to detect changes in aging or anti-aging over the course of months, it will be much easier to obtain high-quality data for prospective anti-aging compounds.
Another solution that aging researchers have discussed is developing frameworks for decentralized clinical trials that could bypass institutional approval but still produce credible results.
There also needs to be a paradigm shift in society, biomedical research, and regulatory bodies like the FDA to recognise and classify aging as a disease.
Open science which aims to make all science accessible to everyone, whether amateur or professional, is would also help to accelerate the rate of research.
Yes, we need improved biomarkers of aging. Once we have biomarkers that are accurate enough to detect changes in aging or anti-aging over the course of months, it will be much easier to obtain high-quality data for prospective anti-aging compounds.
Another solution that aging researchers have discussed is developing frameworks for decentralized clinical trials that could bypass institutional approval but still produce credible results.
There also needs to be a paradigm shift in society, biomedical research, and regulatory bodies like the FDA to recognise and classify aging as a disease.
Open science which aims to make all science accessible to everyone, whether amateur or professional, is would also help to accelerate the rate of research.